Results 171 to 180 of about 43,675 (258)

Repurposing acetyldigitoxin as a potential EZH2 inhibitor for non-small cell lung cancer: a computational and experimental approach. [PDF]

J Comput Aided Mol Des
Ji X, Wang X, Xiu T, Gao M, Lu D.
europepmc   +1 more source

Dissecting diffuse large B‐cell lymphoma heterogeneity: New insights from a state‐specific molecular characterisation

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Integrating DNA and RNA sequencing with digital deconvolution, this study identifies five malignant B‐cell states in DLBCL with distinct mutational and microenvironmental profiles. These states predict survival independently of standard indices, revealing a critical dichotomy between favourable TME‐dependent (S1) and aggressive TME‐independent (S5 ...
Robel Papotti, Filippo Vit, Tamara Bittolo, Federico Pozzo, Stefania Bettelli, Samantha Pozzi, Luca Braglia, Elisa Forti, Arianna Di Napoli, M. Christina Cox, Tamar Tadmor, Pellegrino Musto, Leonardo Flenghi, Martina Quintini, Giovanna R. Mansueto, Sara Galimberti, Valentina Donati, Michele Spina, Alberto Zamò, Andreas Rosenwald, Riccardo Bomben, Stefano Sacchi, Valter Gattei   +22 more
wiley   +1 more source

A dual role of EZH2 in regulating A-to-I RNA editing and mRNA stability through ADAR. [PDF]

Nat Commun
Yi Y, Li Y, Wang R, Yu X, Liu Q, Yum C, Zhang Y, Qiao Y, Szczepanski A, Wu S, Li Q, Fazli L, Shen J, Wang X, Li X, Mu P, Schaeffer EM, Hundley HA, Niu H, Chinnaiyan AM, Wang L, Shi J, Jin J, Dong X, Zhao W, Chen K, Cao Q.   +26 more
europepmc   +1 more source

The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches—A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Neuroblastoma is the most common extracranial solid tumor and contributes the most to pediatric oncology deaths worldwide. Its clinical manifestations are heterogeneous, including relapses, and the prognosis remains poor, especially for high‐risk patients.
Mosammat Jannatul Mawa, Mohammad Shahangir Biswas, Maksudul Haque, Munna Kumar Podder   +3 more
wiley   +1 more source

Prognostic impact of c-MYC and EZH2 expression in small cell and non-small cell lung carcinoma: a single-center retrospective study. [PDF]

Discov Oncol
Karadurmuş B, Sezer E, Arpacı RB, Eser K, Erdoğan S, Erçolak V.   +5 more
europepmc   +1 more source

Unmasking a Composite Lymphoma: Follicular Lymphoma Emerging After Bispecific Antibody Treatment of Marginal Zone Lymphoma

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Composite indolent B‐cell lymphomas may remain unrecognized when one component dominates the clinical presentation. Apparent relapse after therapy may, therefore, represent the emergence of a biologically distinct lymphoma rather than the recurrence of the original disease.
Angel Luis Orosco‐Ttamina, Jiehao Zhou, Juliana Biondo, Farah Hossain, David Viswanatha, Patricia T. Greipp, Natasha Lewis, Javier Munoz   +7 more
wiley   +1 more source

PSMC2 serves as a potential regulatory target of EZH2 in promoting glioma progression via epithelial-mesenchymal transition. [PDF]

Sci Rep
Zhu Y, Li X, Feng P, Dai J, Wang J, Yuan G, Pan Y.   +6 more
europepmc   +1 more source

Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance

MedComm, Volume 7, Issue 8, August 2026.
The graphical abstract is a schematic illustration of the bidirectional crosstalk between tumor plasticity and the tumor microenvironment (TME) in driving metastasis and therapy resistance. Tumor‐intrinsic factors such as genetic mutations and epigenetic reprogramming enable dynamic transitions between epithelial, mesenchymal, and cancer stem cell ...
Gunjan Dagar, Manisha Dagar, Ashna Gupta, Anju Surendranath, Suraja Kumar Das, Mohd Umar Rehmani, Mukesh Tanwar, Sameer Mirza, Muzafar A. Macha, Ammira S. Al‐Shabeeb Akil, Shahab Uddin, Mayank Singh, Ajaz A. Bhat   +12 more
wiley   +1 more source

The MALAT1-EZH2 axis regulates PRC2 activity and promotes the mesenchymal phenotype in pediatric atypical teratoid/rhabdoid tumors. [PDF]

J Neurooncol
Gurbuz M, Tekin C, Ercelik M, Koc SA, Kockar F, Eser P, Taskapilioglu MO, Tezcan G, Erbaykent B, Bekar A, Kocaeli H, Ozsen M, Karabaglı P, Karabaglı H, Bayrak BY, Etus V, Tunca B.   +16 more
europepmc   +1 more source

Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy

MedComm, Volume 7, Issue 8, August 2026.
Barrier‐defined strategies for cold‐to‐hot tumor conversion. Cold tumors include immune‐desert and immune‐excluded states marked by poor antigen visibility, limited T‐cell priming, stromal or vascular exclusion, metabolic stress and suppressive immune programs.
Xiao Ge, Dong Han, Jing Wang, Xinyu Dai, Chen Ma, Feihong Chen   +5 more
wiley   +1 more source